Supplemental figure S8 from Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States

作者：Curtis A. Lachowiez, Georgios Asimomitis, Elsa Bernard, Sean M. Devlin, Yanis Tazi, Maria Creignou, Ulrich Germing, Norbert Gattermann, Amanda Gilkes, Ian Thomas, Lars Bullinger, Konstanze Döhner, Luca Malcovati, Jad Othman, Richard Dillon, Ann‐Kathrin Eisfeld, Deedra Nicolet, Ghayas C. Issa, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo, Farhad Ravandi, Guillermo Garcia‐Manero, Guillermo Montalban‐Bravo, Nigel H. Russell, Mario Cazzola, Hartmut Döhner, Brian J.P. Huntly, Robert P. Hasserjian, Eva Hellström‐Lindberg, Elli Papaemmanuil, Sanam Loghavi · 年份：2026 · DOI：10.1158/2643-3230.32728243 · 研究领域：Acute Myeloid Leukemia Research、Myeloproliferative Neoplasms: Diagnosis and Treatment、Retinoids in leukemia and cellular processes

<p>Overall survival in patients with ELN 2022 favorable-risk, NPM1-mutated AML based on age and co-occurring MR mutations. Patients age <60 with vs. without co-occurring MR mutations experienced inferior survival, while no significant difference in survival was observed in patients age ≥60 years. Reported p-values utilized the cox model Wald test. MR: Myelodysplasia-related mutation.</p>